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Sexual behavior, risk perception, 
and HIV transmission can respond 
to HIV antiviral drugs and vaccines 
through multiple pathways
Stephen Tully1, Monica Cojocaru1 & Chris T. Bauch1,2
There has been growing use of highly active antiretroviral treatment (HAART) for HIV and significant 
progress in developing prophylactic HIV vaccines. The simplest theories of counterproductive 
behavioral responses to such interventions tend to focus on single feedback mechanisms: for 
instance, HAART optimism makes infection less scary and thus promotes risky sexual behavior. Here, 
we develop an agent based, age-structured model of HIV transmission, risk perception, and partner 
selection in a core group to explore behavioral responses to interventions. We find that interventions 
can activate not one, but several feedback mechanisms that could potentially influence decision-
making and HIV prevalence. In the model, HAART increases the attractiveness of unprotected sex, 
but it also increases perceived risk of infection and, on longer timescales, causes demographic 
impacts that partially counteract HAART optimism. Both HAART and vaccination usually lead to 
lower rates of unprotected sex on the whole, but intervention effectiveness depends strongly on 
whether individuals over- or under-estimate intervention coverage. Age-specific effects cause sexual 
behavior and HIV prevalence to change in opposite ways in old and young age groups. For complex 
infections like HIV—where interventions influence transmission, demography, sexual behavior and 
risk perception—we conclude that evaluations of behavioral responses should consider multiple 
feedback mechanisms.
Over the past few decades, our growing understanding of factors contributing to HIV transmission 
has improved HIV control efforts. Partner selection and safe sex practices are now recognized as major 
determinants of HIV prevalence1,2 and have been analyzed through mathematical models focussing on 
behavioral aspects of HIV and other sexually infectious diseases3–6. This remains an important issue, par-
ticularly with data indicating that, despite greater public awareness, HIV incidence rates are once again 
increasing in men who have sex with men (MSM) in the United States7. Fortunately, treatment options 
such as Highly Active Antiretroviral Treatment (HAART), are becoming more widely available, and an 
effective prophylactic HIV vaccine is now a realistic goal8.
However, implementing treatment and prevention programs may have unintended consequences. 
Interventions like HAART that delay progression to AIDS may reduce the fear of living with HIV/AIDS 
(so-called ‘HAART optimism’). This in turn may cause individuals to choose riskier sexual behaviors, 
thereby increasing HIV transmission more than would have been the case if sexual behavior did not 
change due to HAART9,10. Alternatively, both prophylactic vaccines and HAART may reduce HIV preva-
lence, which in turn may also cause some individuals to become complacent about their risk of infection 
and thus increase their risky sexual behavior, thereby also increasing HIV transmission. Both types of 
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responses are examples of ‘policy resistance’, where the population’s response to an intervention tends to 
undermine the intervention11. This could potentially lead to an increase in HIV prevalence, particularly 
in high risk groups such as MSM (men who have sex with men)12.
As such, it is important to assess a population’s perception of how the risks associated with contract-
ing HIV might evolve due to introducing HAART or prophylactic vaccines, and the resulting changes in 
disease dynamics. Cross-sectional surveys can provide valuable information on a population’s perception 
and behavior at a specific time. However, it is difficult to extrapolate from surveys to determine how 
perception and behavior might evolve under different circumstances, such as when a new intervention 
is introduced to the population (indeed, it is only possible to gauge how individual’s think they would 
respond under different circumstances). In contrast, mathematical models can be used to extrapolate to 
different circumstances, but they also require making simplifying assumptions. Combining insights from 
both mathematical models and surveys may provide a clearer understanding of how policy resistance to 
HIV interventions can emerge. Using empirically informed mathematical models in particular may help 
us understand how HIV interventions change the interplay between individual risk perception, sexual 
behavior, and population disease dynamics.
HAART optimism is the focus of many surveys designed to measure how risk perception evolves 
after introducing HIV interventions. HAART optimism is defined as a consequence of HAART that may 
lead to a change in behavior, such as an increase in unprotected sex, or a decreased likelihood to remain 
on medication. A number of studies have explored the existence of HAART optimism, and the factors 
that may drive its emergence. In terms of treatment commitment, one such study comprising of a mass 
questionnaire found that 57% of optimists reported not always taking their HAART, compared to 29% of 
the individuals characterized as pessimistic13. The study authors concluded that treatment centres should 
more closely monitor patients’ prognostic beliefs.
Studies have come to varying conclusions regarding the impact of HAART optimism on sexual behav-
ior. Some studies have found an increased level of risky behavior in HAART patients9,10,14. For example, 
Huebner et al. conducted a mass survey to better understand the relation between gay and bisexual men’s 
beliefs about HAART and sexual risk behavior. Using study participant data, Huebner found evidence 
of risk perception changing due to treatment. Men who believed that HAART decreased the risk of 
HIV transmission expressed reduced intentions to use condoms for anal sex and were also more likely 
to have engaged in unprotected anal intercourse with a casual partner. The behavioral surveys extend 
to the impact of potential HIV vaccines on sexual behavior. Lee et al. developed an HIV attitudes scale 
to predict vaccine acceptability. The survey randomly sampled individuals attending STD clinics and 
needle exchange sites. Risk compensation was found to be positively and significantly associated with 
vaccine acceptability, indicating individuals open to adopting the HIV vaccine perceived less of a need 
for protection through condom use15.
Other studies have found that HAART caused no change in risky behavior16, or decreased risky behav-
ior17. For instance, Remien et al.’s cross-sectional study in MSM found no increased risk behavior asso-
ciated with HIV positive individuals being on HAART16. Stephenson et al. conducted a cross-sectional 
study of HIV positive homosexual men, finding that men on HAART had fewer sexual partners, less 
unprotected anal intercourse and fewer acute sexually transmitted infections than men not on HAART. 
These cross-sectional studies studies illustrate the potential complexity of perceptual and behavioral 
responses to interventions. Differing study conclusions may reflect different study populations or study 
design. Moreover, because disease dynamics unfold over time, cross-sectional studies may fail to capture 
how disease dynamics may also influence risk perception and sexual behavior.
Epidemiological models such as disease transmission models or game theoretical models can be used 
to address how disease dynamics unfold over time and influence risk perception and behavior in a single 
population3–6,18–20. Previous disease transmission models have addressed the issue of how HAART opti-
mism may occur and how it may influence disease dynamics and/or behavior. For example, Ramadanovic 
et al. focus on changing risk behaviors in the context of preventive HIV treatment3. The authors create 
a deterministic compartmental model that treats HIV risk behavior and infection as linked processes 
wherein the individual increases risk behavior as a precursor to contracting HIV. Ramadanovic et al. 
demonstrate that HIV incidence and prevalence only decline above threshold levels of HAART cover-
age, indicating a strong connection that is dependent on risk behavior parameter values. Results showed 
that expanding HAART coverage combined with interventions aimed to reduce risky behaviors would 
amplify the preventative impact and possibly eliminate the HIV epidemic. A model of HIV and vaccina-
tion by Smith? et al., defines a fitness ratio as the average number of secondary HIV infections caused by 
an infected vaccinated individual, divided by the basic reproduction number21. By holding risk behavior 
constant, they were able to determine thresholds at which HIV prevalence would increase instead of 
decrease due to the vaccine, in the case that disease modifying vaccines provide only a low degree of 
protection against infection and/or generate high fitness ratios. Their findings report that the success of 
a vaccination campaign hinges upon the fitness ratio, the proportion of the population that were vacci-
nated, and the degree of change of risk behavior in unvaccinated infected individuals21.
Game theoretical and other behavioral modeling frameworks formalize how individuals make deci-
sions in a strategic environment. Schroeder et al. used a signalling game to investigate sexually trans-
mitted disease epidemics. They constructed simple signalling game models which demonstrate that 
uninfected individuals engage in high-risk sex with both uninfected and potentially infected partners, if 
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the perceived prevalence of infection is sufficiently low22. Applying a decision-making model to infec-
tious diseases, Auld investigated how a population’s choices and beliefs impact infectious diseases and 
the spread of HIV. Using a dynamical model, he showed that the success of an intervention is highly 
dependent on whether the population anticipates the presumed changes and adjusts their behavior. This 
demonstrated that a population’s behavior leading up to introduction of an intervention could impact its 
spread, and thus is important to consider23.
Much of the previous literature on HIV transmission and behavioral modelling focuses on population 
responses to interventions based on single mechanisms, such as exploitation of herd immunity. Here, 
our objective is to understand how populations can respond to the introduction of interventions through 
multiple mechanisms (pathways). We develop an agent-based model to explore the impact of coevolu-
tion of risk perception, sexual behavior, and HIV transmission dynamics in the context of prophylactic 
vaccines and HAART. Our model captures the interaction between the sexual partner selection process 
(as it depends upon time-evolving individual risk perception) and HIV disease dynamics, and how both 
respond to the introduction of HAART and prophylactic vaccines. Our objective is to explore poten-
tial mechanisms that may either lead to, or prevent, the development of policy resistance against those 
interventions. Each individual uses a utility function to decide whether to practice protected sex (PS), 
unprotected sex (US), or no sex (NS) with the other individual they are interacting with. (Utility is an 
abstract measure of preference that individuals can use to compare and rank different possible out-
comes). This approach helps identify how decisions are formed, and how interactive decision-making 
between HIV+ and HIV− individuals helps determine spread of HIV. We introduce heterogeneity into 
the model in the form of age structure, allowing us to explore age-specific effects. With a more informed 
understanding of how risk perception evolves, and how it reacts to the introduction of HAART and 
prophylactic vaccines in a population, we can better understand the changes in behavior associated with 
new treatment options. We use the model to shed light on the complex nuances of HAART optimism 
and vaccine policy resistance.
Methods
The model represents HIV transmission and partner selection dynamics in a core group of individuals 
with higher partnership turnover, such as a core group of MSM. This was motivated by studies such as 
Gomes do Espirito Santo et al., that describe how the clients of male sex workers can act as a bridge for 
HIV transmission to the general population24. Sex workers and their clients are also the target of many 
prevention initiatives, which is why such groups were chosen as our main focus. The model is based 
on a previous agent-based partner selection model25. The previous model is a simplified representation 
of the co-evolution between risk perception and HIV prevalence, within a homogeneous population of 
MSM over a relatively short amount of time. Individuals are randomly paired and, while aware of their 
own status, are unaware of their partner’s status. The game they play represents a strategic interaction 
between the individuals, wherein utilities are weighed and an outcome, dependent on how an interaction 
has progressed, is chosen.
The previous model was modified to incorporate: (1) age structure, including age-specific sexual 
activity levels and mixing patterns, (2) vital dynamics, including recruitment, death and aging, (3) a 
modified representation of partner selection, (4) modifications to utility functions and risk perception 
dynamics to accommodate the presence of HAART and/or vaccine programs in the population, and (5) 
the impact of HAART and prophylactic vaccines on HIV infection probabilities and HIV natural history.
Vital Dynamics and Partner selection. Every time-step represents one month, after which each 
individual’s age counter is advanced by one month. New individuals enter the sexually active population 
at age 15 years26. All individuals will exit the population through natural death at 79 years of age, or 
preemptively by death due to AIDS.
In each time step, there is a probability that an individual engages in an encounter that may lead to sex 
(i.e., plays the ‘risky sex game’). The probability of engaging is highest in 20-year-olds and declines with 
age (see Supplementary Table S1)27,28. If an individual engages, they engage with a randomly selected 
individual who is within 8 years of their own age26. There is a random chance that any given actor will be 
assigned to be “Actor 1” in an interaction. Actor 2 represents the randomly chosen individual fitting the 
age requirement, and must not be engaged in a current interaction. Actor 2 must interact with Actor 1, 
if Actor 1 decides to interact with Actor 2 (although they do not have to choose sex). Individuals decide 
by calculating utilities based on the value of sex (protected or unprotected), the risk of contracting HIV 
(which depends on behavior of the other individual, perceived , and perceived vaccine coverage), the 
health impact of contracting HIV, and how the impact might be modified by HAART (see following 
subsection on HAART). A detailed description of the interaction between individuals in an encounter 
appears in the Supplementary material.
Risk perception dynamics. In order to model risk perception evolution, we define bt to be an indi-
vidual’s personal risk assessment at time t. Each actor has a specific bt value. This value varies over the 
course of the simulation as actors update their bt-value based on their encounters. Each actor draws 
their initial bt-value b0 randomly from a normal distribution of mean μ = 0.05 and standard deviation 
σ = 0.1; sampled values less than 0 or greater than 1 are discarded. We chose a relatively small value for 
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the initial bt-value because recruited individuals in the model are younger, and both the perceived preva-
lence of HIV in a population as well as the perceived risk of contacting HIV or other STIs are less within 
younger age groups29–31. During an interaction, an individual will either increase their risk assessment 
or decrease it depending on the offers they are receiving. If Actor 1 offers US, Actor 2 increases their 
bt-value according to
α α= + ( − ) ∗ , ( )−b b1 1t t 1
where α is called the “historical influence parameter”, since it measures how much of bt is from past 
encounters versus the current offer. If Actor 1 offers PS, then Actor 2 decreases their bt-value according to
α= ( − ) ∗ . ( )−b b1 2t t 1
Risk perception changes by adjusting the assigned utilities as well as bt-value. Utilities are assigned 
to possible actions, and an Actor’s decision is dependent on the weight of the utility and their risk per-
ception. The formulation for utilities and calculating the expected utility is similar to that described in 
the previous paper25 and is described further in the supplementary material. Prior to intervention, the 
utility for US for an HIV− individual engaging with an HIV+ individual is UUS = − 50. However, with 
the introduction of HAART and its effects on lowering transmission and increasing life span, the UUS 
is increased to account for this. Depending on the HAART coverage (ρ), and k influencing the over or 
under-estimation of coverage in the population, the resulting UUS can become more appealing than NS.





This expression captures how the utility for risky sex, in the presence of HAART, is a function of 
both utility for unprotected sex without the availability of HAART (UUS) and the utility of unprotected 
sex if HAART is available to them (UUS + d), weighted according to the perceived availability of HAART 
in the population (ρ modified by misperception of true HAART coverage, k). By adjusting the utility, 
the choices made by individuals are altered and risky sex is perceived as more attractive under HAART.
The introduction of an HIV vaccine also changes the risky sex game. An HIV− individual that has 
been vaccinated and has acquired immunity will then alter how they update their bt-value as well as the 
UUS for engaging with an HIV+ individual, by changing this to be the same utility as interacting with an 
HIV− person. Once the Actor however realizes that they are no longer protected, they will revert back 
to an HIV− utility set (See Table 1). Once the vaccine is introduced, the method by which an individual 
updates their bt-value will change. Updating when someone offers US will now also be dependent on 
how the individual perceives the current vaccination coverage of the individual they are interacting with. 
When an individual is offered US, they will update their bt-value according to:
α ρ α= ∗ ( − ) + ( − ) ∗ . ( )−b b1 1 4t i
k
t 1
where we assume individuals know the age of the individual making the US offer, and ρi is the vaccine 
coverage in the age group i of the individual who is making the offer (see Table 1 for ρi values; ρi is set 
Term Definition Value
ρi
Treatment coverage (HAART or Vaccine). HAART 
coverage is independent from age group. Vaccine 
coverage is is implemented at age 15, with the age 
i impacting Equation 4
0.75 (i = 15–25), 0 (i = 26+ )
d adjustment to UUS due to HAART 20
k parameter determining over- or under-confidence in coverage 1
lV duration of vaccine protection 10 years (normal dist. 10, 3)
It
times at which individuals are tested for remaining 
protection, post-vaccination 5, 10, and 15 years
V vaccine efficacy 0.9
UUS(− , + )
utility for a HIV− individual to have US with a 
HIV+ individual, in absence of protection from 
the vaccine
− 50
UUS(− , + )(V)
utility for a HIV− individual to have US with a 
HIV+ individual, while assuming protection from 
vaccine.
100
Table 1.  Parameter definitions and parameter values corresponding to HAART and vaccination 
scenarios.
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to zero 10 years after vaccination because we assume individuals know that the vaccine immunity wanes). 
We can adjust k to reflect an individual’s belief of the prevalence of the vaccine in the population. This 
parameter is included because of studies such as Herlitz et al. showing that individuals do not have per-
fect knowledge of HAART coverage in the population32. The adjustments to utilities, and changes to how 
individuals update their risk assessment, describe possible responses due to introducing HAART and/or 
prophylactic vaccines. Analysis of the individual risk perception time evolution aids in understanding 
risk perception dynamics.
HIV transmission and natural history. A person infected with HIV passes through the acute, 
latent, pre-AIDS, and AIDS stages. The duration of each stage is a fixed time interval (Supplementary 
Table S2). Individuals die at the end of the AIDS stage (or the AIDS with treatment stage, see subsec-
tion on HAART below). The different stages of infection are illustrated by Supplementary Figure S1. 
During unprotected sex, an infected person infects a susceptible person with a probability dependent on 
their current infection stage, with the relative infectivity during the various stages being highly variable 
(Supplementary Table S3). However, individuals in the AIDS stage are assumed not to engage in sexual 
encounters at all, due to symptomaticity. In order to account for newly infected individuals unaware of 
their status who continue under the assumption they are HIV− , we introduced ζ = 0.1 (Table 2), mean-
ing that an HIV infected individual has a 10% chance of being tested (and thereby discovering their true 
HIV status) per timestep (one month). We note that the proportion of individuals unaware of their HIV 
status varies significantly between populations, and in many populations this proportion is higher than 
what we have assumed here33.
HAART. There is considerable debate as to when HAART should be initiated, since the benefits of 
early treatment can be counteracted by antiviral drug toxicity34. Here, we assume that at the end of the 
latent stage, an individual enters HAART with probability ρ, where ρ represents treatment coverage. 
HAART lengthens life, facilitates relative reduction in transmission, and improves the utility that an 
HIV− individual associates with unprotected sex, by an additive factor d (see Supplementary material). 
Since HAART availability improves the UUS, it affects whether individuals offer, or accept, unprotected 
sex, and hence it may influence the perceived risk parameter, b.
The proportion of people living with AIDS who were receiving HAART increased from 74% in 2005 
to 90% in 2008 in San Francisco35. In lower-income countries, the coverage is much lower but is rapidly 
increasing36. Here we consider values of ρ with a baseline of 75% and simulate coverage from 0 to 100%. 
In simulations, we allow the population to come to an epidemiological and demographic equilibrium 
before introducing HAART into the population.
Prophylactic HIV Vaccine. Drawbacks of HAART include drug resistance, drug toxicity, and the 
need to know HIV status and CD4 count before offering intervention. As a result, more than 30 HIV 
vaccines are being tested in human clinical trials worldwide8, including at least one based on a genetically 
modified killed whole virus37. A prophylactic vaccine would mean that a certain percentage of vaccinated 
HIV− individuals are protected from infection, even if they engage in unprotected sex. As a result, 
prophylactic vaccines could impact how individuals update their risk perception based on their partner 
actions, and knowledge of vaccine coverage in the population.
A randomly chosen proportion ρ of 15-year-olds entering the sexually active population receive the 
vaccine, which has all-or-none efficacy  = %90V . Similar to the practice with hepatitis B vaccine in 
some jurisdictions, we assume that individuals are tested immediately after vaccination, and thus are 
aware if the vaccine worked for them. Individuals who were not vaccinated, or in whom the vaccine was 
ineffective, do not change their utilities. However, those who are efficaciously protected increase their 
utility for unprotected sex, since they cannot be infected (see Supplementary Material for details).
Term Definition Baseline value
b0
Initial bt-value: initial value of bt sampled from a beta 
distribution with mean 0.05 and a standard deviation of 0.1. 0.05
α Historical influence parameter: measures how much of the bt-value will be based on past experience.
0.015
τ
Baseline transmission probability: probability of HIV 
transmission from an HIV+ actor to an HIV− actor 
through US. This value is modified according to stage of 
infection (see Supplementary Table S3)
0.0242
UPS Protected sex utility. 50
ζ Probability an individual who identifies as HIV− will seek testing to determine if they are infected. 0.1 per timestep
Table 2.  Parameter definitions and parameter values for baseline scenario.
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Vaccine scheduling recommendations depend on various factors, including epidemiological, social, 
and health economic factors. Our assumption for HIV vaccine program design was based on experience 
with the HPV vaccine, which was first made available in 11–15 year olds38. The reason for this is that 
the HPV vaccine is prophylactic (similarly to our assumed HIV vaccine) and thus, by definition, only 
protects susceptible persons, not infected persons. Hence, it is more efficient to vaccinate age groups 
where the proportion of susceptible individuals is highest, so vaccination is not wasted on individuals 
who are already infected. The model does not however, incorporate catch-up programs which would 
likely be rolled out in older age classes.
The duration of protection for an efficaciously vaccinated individual is taken from a normal distribu-
tion with a mean 10 years and a standard deviation of 3 years. Vaccines are tested 5 and 10 years after 
being vaccinated and if the test indicates that their vaccine protection has ceased, the individual will 
change their utility back to that of an HIV− individual, otherwise they will continue with the utility of a 
vaccine-protected HIV− individual. At 15 years post-vaccination, individuals assume they are no longer 
protected and revert to the utility function of an unprotected HIV− individual. As no HIV vaccine cur-
rently exists, our testing assumption is based on practice associated with the Hepatitis B vaccine, which 
also protects against a dangerous sexually transmitted infection, and for which individual immunity after 
vaccination is tested in some jurisdictions39.
Results
The partner selection model is based on a previous agent-based model used to explore the coevolution 
of risk perception, partner selection, and HIV transmission25. In the present model, individuals in an 
age-structured core group population (1) engage with others, (2) decide whether to have protected or 
unprotected sex based on their own status, the perceived probability that the other person is HIV+ , and 
utilities, as modified by the presence of HAART and vaccines, and (3) may transmit the infection if they 
have unprotected sex. The model is outlined in the Methods Section.
We investigate changes in the population caused by HAART or prophylactic vaccines by comparing 
the dynamics with and without the interventions.The simulations are run to equilibrium before an inter-
vention is introduced. Because the model is necessarily complicated on account of exploring multiple 
potential feedbacks on perception and behavior, we focus on the impact of these interventions separately 
and do not investigate scenarios where both are applied, leaving this to future work.
We explore how these changes depend on model parameters governing vaccine and treatment cov-
erage, vaccine efficacy, duration of protection, risk perception parameters, and transmission rates. The 
interventions are implemented at year 50 of the simulation in all figures, by which time the population 
has reached equilibrium. We also vary the utility associated with a sexual act, the value of which con-
tributes to the decision making process. Model outcomes include population sizes, HIV prevalence, the 
perceived probability that the other person is HIV+ (which we hereafter refer to simply as “perceived 
infection risk”), and per capita number of unprotected sex acts (US) (i.e. US acts per HIV− individual, 
providing a gauge of risky behavior before and after interventions), broken down by age and HIV status. 
Baseline parameter values and utilities appear in Table 2 and  Table 3 respectively. We use these param-
eter values in all simulations except when stated otherwise.
Baseline scenario: no HAART or vaccines. In the absence of interventions such as HAART or 
vaccines, the population converges to equilibrium levels of population size, HIV prevalence, and per-
ceived infection risk (b) (Figs  1 and 2). HIV prevalence is highest in 20–29 and 30–39 year olds. The 
average perceived infection risk bt is similar to the HIV prevalence, although HIV− individuals tend to 
underestimate HIV infection risk and HIV+ individuals tend to slightly overestimate it. The perceived 
infection risk tends to be lowest in 15–19 year olds.
As expected, increasing the transmission rate τ increases HIV prevalence, as well as the average 
bt-value (perceived infection risk) (Supplementary Figure S2). Increasing the utility for protected sex 














HIV+ HIV+ 100 50 0 US > PS > NS
HIV+ HIV− 100 50 0 US > PS > NS
HIV− HIV+ − 50 50 0 PS > NS > US
HIV− HIV− 100 50 0 US > PS > NS
Table 3.  Utilities for Actor 1, given status of Actor 2, in absence of interventions. This outlines the 
preferences for different sexual acts given an individual’s status.
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S3). This occurs because having a more attractive utility for PS reduces the spread of HIV and hence the 
perceived risk of contracting HIV.
Impact of HAART on risk perception, sexual behavior, and HIV prevalence. Parameters for the 
baseline HAART scenario appear in Table 1. HAART decreases the transmission rate and thus reduces 
the incidence of new HIV cases. However it also increases the lifespan of HIV+ individuals, such that 
the net impact of HAART is a small net increase in the number of HIV+ individuals in the population 
(Fig. 3a). Significant reductions in the number of HIV+ individuals in the 15–39 year old age range due 
to reduced incidence are offset by significant increases in the number of HIV+ individuals in the 40+ 
age range due to longer lifespans and delayed age at infection (Fig.  3d). As a result of reduced trans-
mission rates, the number of HIV− individuals grows considerably, causing a decrease in overall HIV 
prevalence (Fig. 3a,f).
In the short-term, HAART optimism causes a transient spike in the per capita rate of unprotected 
sex (US) between HIV+ and HIV− individuals in all age groups (Fig.  4a versus Fig.  2a). There is a 
Figure 1. Baseline scenario with no interventions. (a) number of HIV—(green) and HIV+ (red) 
individuals in the population; (b) average bt-value for HIV—individuals by age, 15-20-year-olds (red), 
20–30 (orange), 30–40 (yellow), 40–50 (green), and 50+ year-olds (blue); (c) average bt-values for HIV+ 
individuals by same age groups; (d) number of HIV+ individuals by the same age groups, and with black 
representing the total number of HIV+ individuals; (e) total average bt-value for HIV+ (red) and HIV—
(green) populations; (f) HIV prevalence (percentage of the population currently infected).
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corresponding increase in the total number of US acts, driven primarily by older age groups where the 
HIV+ population is expanding (Fig. 4b versus Fig. 2b). HAART makes unprotected sex more attractive 
to HIV− individuals by increasing the utility of US through the parameter d, which in turn increases 
the number of US offers.
However, two other pathways partially counteract the effect of HAART optimism. On account of 
Equation 4, the increase in the number of US offers also increases the average value of bt representing the 
perceived infection risk, across most age groups, and for both HIV+ and HIV− individuals (Fig. 3b,c,e 
versus Fig.  1). The increase in perceived infection risk has a protective effect on the population, by 
making HIV− individuals more likely to believe the other actor is HIV+ (since more US offers are 
being made). Additionally, on account of fewer new infections, a gradual but significant expansion of 
the HIV− population occurs over time (Fig. 4(c) versus Fig. 2(c)). This growth in the HIV− population 
exceeds the expansion of the HIV+ population (Fig. 4(d) versus Fig. 2(d)), resulting in a net reduction 
Figure 2. Baseline scenario with no interventions. (a) total number of − /+ US acts (number of 
unprotected sex acts between HIV− and HIV+ pairs) per year divided by number of HIV—individuals in 
that age cohort at the end of the year, for age groups 15–20-year-olds (red), 20–30 (orange), 30–40 (yellow), 
40–50 (green), and 50+ year-olds (blue), and cumulative number of individuals across all age groups 
(black); (b) total number of − /+ US acts per year, for same age groups; (c) number of HIV—individuals in 
each age cohort at the end of the year, for same age groups.
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in HIV prevalence. This means that any given encounter is more likely to be with an HIV− person 
than an HIV+ person. As a result, for younger age classes, and across all age classes on average, the 
per capita rate of US between HIV+ and HIV− actors falls to an equilibrium value that is below the 
baseline scenario with no HAART, although in older age groups it falls to a level that remains above the 
baseline scenario with no HAART. Hence, in the long run, HAART results in less US being practiced by 
HIV− individuals on average, but not for older individuals. Both protective pathways tend to decrease 
the per capita number of unprotected sex acts between HIV+ and HIV− individuals in the long term, 
so that the transient spike in the per capita rate of US between HIV+ and HIV− actors due to HAART 
optimism is followed by a gradual decrease.
In summary, HAART causes HAART optimism in the short term along with a transient spike in 
unprotected sex acts between HIV+ and HIV− individuals. However, in the longer term, it activates 
other pathways that provide protective effects by modifying risk perception and population composi-
tion. The effect of HAART on multiple pathways—some of which are protective and some of which are 
not—illustrates the complex nature of interactions between interventions, individual risk perception and 
Figure 3. Baseline scenario for HAART intervention. (a) number of HIV− (green) and HIV+ (red) in 
the population; (b) average bt-value for HIV− individuals by age, 15–20-year-olds (red), 20–30 (orange), 
30–40 (yellow), 40–50 (green), and 50+ year-olds (blue); (c) average bt-values for HIV+ individuals by same 
age groups; (d) number of HIV+ individuals by the same age groups, and with black representing the total 
number of HIV+ individuals; (e) total average bt-value for HIV+ (red) and HIV− (green) populations;  
(f) HIV prevalence (percentage of population currently infected).
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behavior, and population dynamics. This suggests one reason why different surveys of HAART effects 
conducted at different times in different populations might provide different results9,10,16,17. These results 
also illustrate how the impact of HAART can evolve over time, and change from net negative influences 
to net positive influences as the disease dynamics unfold.
Univariate sensitivity analysis for the impact of HAART on the utility for unprotected sex (d). 
At baseline parameter values, the benefits of HAART in reducing transmission and increasing the per-
ceived infection risk are strong enough to counteract how HAART optimism makes US more attractive, 
resulting in a net reduction in HIV prevalence and incidence. HAART optimism operates through the 
model parameter d, which increases the utility of unprotected sex (Equation 3).
As the value of d is increased above the baseline value d = 20, US becomes increasingly attractive, 
which increases actual post-treatment HIV prevalence as well as the average perceived infection risk 
Figure 4. Baseline scenario for HAART intervention. (a) total number of − /+ US acts (number of 
unprotected sex acts between HIV− and HIV+ pairs) per year divided by number of HIV—individuals in 
that age cohort at the end of the year, for age groups 15–20-year-olds (red), 20–30 (orange), 30–40 (yellow), 
40–50 (green), and 50+ year-olds (blue), and cumulative number of individuals across all age groups 
(black); (b) total number of − /+ US acts per year, for same age groups; (c) number of HIV—individuals in 
each age cohort at the end of the year, for same age groups.
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(Supplementary Figure S4). For d > 60, the post-treatment HIV prevalence exceeds the pre-treatment 
HIV prevalence: for these parameter values, the effects of HAART optimism cause a net increase in HIV 
in the population. At d = 60 for an HIV− actor, US with an HIV+ actor still provides a lower utility than 
PS. Hence, sufficiently strong HAART optimism could actually cause a net increase in HIV prevalence.
Decreasing d has the opposite effect, making US under HAART less attractive to HIV− individu-
als and thus decreasing HIV prevalence (with an accompanying decrease in perceived infection risk) 
(Supplementary Figures S5, and S6).
Univariate sensitivity analysis for amount of over- or under-estimation of population HAART 
coverage (k). The parameter k controls whether individuals over-estimate or under-estimate the 
amount of HAART coverage in the population. When k > 1 (respectively k < 1), individuals underesti-
mate (respectively, over-estimate) the amount of coverage. This has implications for whether they think 
the other actor is HIV+ or not. If individuals underestimate HAART coverage (k > 1), then offers of US 
are more likely to be interpreted as meaning the other actor is HIV+ , rather than being an HIV− person 
exhibiting HAART optimism, meaning their perceived prevalence of HIV will increase. Hence, they opt 
for protected sex, causing a decrease in HIV prevalence. This is indeed what is observed in simulations: 
as k increases, HIV prevalence decrease (Supplementary Figure S7). However, the average bt-value also 
decreases, since a decrease in HIV prevalence also causes a decrease in US offers. Hence, the decrease in 
US offers is offset by an increase in the likelihood that they are interpreted as evidence of HIV+ status, 
if individuals under-estimate HAART coverage in the population. The opposite happens for k < 1.
Univariate sensitivity analysis for coverage (ρ), the transmission rate (τ) and the utility 
for protected sex (UPS). Increasing the population coverage of HAART (ρ) decreases HIV prev-
alence, while the average perceived infection risk, bt, increases slightly, at baseline parameter values 
(Supplementary Figure S8). Increasing the transmission rate (τ) increases the HIV prevalence, and the 
perceived infection risk among HIV+ individuals, but has no effect on the perceived infection risk 
among HIV− individuals (Supplementary Figure S9). This occurs due to the structure of the game and 
the utilities assigned to the available actions (See Supplementary Section Understanding the evolution of 
bt-values). Finally, increasing the utility associated with protected sex (UPS) makes it more attractive, and 
decreases HIV prevalence as well as perceived infection risk among both HIV+ and HIV− individuals 
(Supplementary Figure S10).
Impact of prophylactic vaccination. The baseline parameters for prophylactic vaccination appear 
in Table 1. Whereas HAART is provided to HIV+ individuals, prophylactic vaccination is provided to 
HIV− individuals. We assume an efficaciously vaccinated HIV− individual derives the same utility for 
US as an HIV+ individual, since they cannot acquire the infection while protected, which makes US 
offers attractive to vaccinated individuals.
Implementation of a vaccination program at year 50 covering 75% of entering 15-year-olds, and 
providing protection for approximately 10 years, causes a rapid decrease in infected 15-29-year-olds 
(Fig. 5d). The intervention causes a particularly rapid reduction in HIV prevalence in the 15–20 year-old 
age group (Fig. 5d). Because HIV becomes so rare in this group, its dynamics are highly stochastic and 
caused corresponding changes in the offers of US versus PS, which in turn causes great variability in 
the value of bt over time in HIV+ individuals in this age group (Fig. 5c). A delayed and more moderate 
decrease in HIV prevalence occurs in infected 30–39 year-olds, but the number of infected individu-
als actually increases in 40+ year-olds (Fig. 5d). This occurs because individuals who normally would 
have been infected when young, are no longer becoming infected due to the vaccine, but instead they 
become infected when they are older and vaccine protection has worn off. As a result, the total number 
of infected individuals remains relatively constant after vaccination is introduced, although the number 
of HIV− individuals increases, which reduces the HIV prevalence (Fig. 5a,f).
Individuals have some awareness of the age at which the vaccine is administered, the vaccine cover-
age, and the duration of protection, although they may overestimate or underestimate the actual vaccine 
coverage according to the parameter k. The vaccine program decreases the perceived prevalence of HIV 
among HIV− individuals under 29 years of age, causes a slight increase in perceived prevalence in 30–39 
year olds, but it has no effect in 40+ year olds (Fig. 5b). The slight increase in 30–39 year olds occurs 
because some of those individuals mix with individuals in younger age classes who are still protected by 
the vaccine and hence have a preference for US.
Results are similar among HIV+ individuals, except the perceived prevalence decreases slightly in 
30+ year olds (Fig.  5c). The decrease in perceived prevalence in younger age categories occurs due to 
awareness of the vaccine program, meaning that individuals are more likely to interpret an offer of US 
as evidence of vaccinated status. Hence, the decline in perceived prevalence tracks the decline in actual 
prevalence, even though US is still offered and practiced.
After the vaccine program is implemented, the rate of US acts between HIV+ and HIV− individuals 
per HIV− individual decreases in individuals below 39 years of age; remains constant in individuals 
40–49 years old; and increases significantly in individuals 50+ (Fig. 6a). The decline in younger age cat-
egories reflects the significantly diminished number of HIV+ individuals in those age categories: there 
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are simply not enough HIV+ individuals for per capita rates of US between HIV+ and HIV− actors 
to increase. In older age categories, the increase in per capita unprotected sex by HIV− individuals is 
caused by the increased population size of HIV+ individuals, due to the waning of protection from the 
vaccine.
Because (1) perceived infection risk tracks HIV prevalence (Fig. 5b,c) and (2) the per capita rates of 
unprotected sex are driven by changes in the numbers of HIV+ individuals in the age cohorts rather 
than behavioral changes stemming from altered utility functions per se, the negative feedbacks stimu-
lated by prophylactic vaccination are limited. Although vaccine-protected individuals practice more US 
than without the vaccine, this does not translate into higher HIV prevalence. And, because vaccinated 
individuals are always HIV− , the direct impact on the other actor is minimal.
However, these results suggest that a booster program may be beneficial in older age categories, if vac-
cine protection wanes rapidly enough. Moreover, we did not explore the possibility of vaccine exemption 
due to vaccine-generated herd immunity, which could reduce vaccine coverage below socially optimal 
Figure 5. Baseline scenario for vaccine intervention. (a) number of HIV− (green) and HIV+ (red) in the 
population; (b) average bt-value for HIV− individuals by age, 15–20-year-olds (red), 20–30 (orange), 30–40 
(yellow), 40–50 (green), and 50+ year-olds (blue); (c) average bt-values for HIV+ individuals by same age 
groups; (d) number of HIV+ individuals by the same age groups, and with black representing the total 
number of HIV+ individuals; (e) total average bt-value for HIV+ (red) and HIV− (green) populations; (f) 
HIV prevalence (percentage of population currently infected).
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levels. The model also assumes individuals know their immuno-protection status, and that their vaccine 
protection can wane over time, which may not occur universally in real populations.
Univariate sensitivity analysis for the over- or under-estimation of population vaccine cover-
age (k). For higher values of k, such that individuals under-estimate population vaccine coverage, the 
perceived infection risk increases since individuals interpret US offers as evidence of HIV+ status. This 
causes HIV prevalence to decrease significantly compared to baseline, since PS becomes more attractive 
than US under such circumstances (Supplementary Figure S11). On the other hand, lower values of k 
mean individuals over-estimate population vaccine coverage, such that perceived infection risk decreases 
instead of increasing, and HIV prevalence declines only slightly compared to pre-vaccine prevalence 
(Supplementary Figure S12). Hence, underestimation of population vaccine coverage can significantly 
reduce the effectiveness of prophylactic HIV vaccination programs, due to the tendency to accept US 
Figure 6. Baseline scenario for vaccine intervention. (a) total number of − /+ US acts (number of 
unprotected sex acts between HIV− and HIV+ pairs) per year divided by number of HIV—individuals in 
that age cohort at the end of the year, for age groups 15–20-year-olds (red), 20–30 (orange), 30–40 (yellow), 
40–50 (green), and 50+ year-olds (blue), and cumulative number of individuals across all age groups 
(black); (b) total number of − /+ US acts per year, for same age groups; (c) number of HIV—individuals in 
each age cohort at the end of the year, for same age groups.
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more often. These observations are borne out across a range of value for k (Supplementary Figure S13). 
Also, changes in k have a greater effect for prophylactic vaccination than for HAART (Supplementary 
Figure S7).
Univariate sensitivity analysis for vaccine coverage (ρ), vaccine efficacy (), transmission rate 
(τ) and utility for protected sex (UPS). Increasing the vaccine coverage ρ or the utility for protected 
sex UPS decreases both actual and perceived infection risk, as expected (Supplementary Figures S14, S15). 
In contrast, increasing the vaccine efficacy  decreases the HIV prevalence but slightly increases the 
perceived infection risk (Supplementary Figure S16). This occurs because a higher vaccine efficacy pro-
tects more vaccinated individuals and thus leads to more US offers, however, individuals do not take 
vaccine efficacy into account in their risk perception, only vaccine coverage. Increasing the transmission 
rate τ increases the HIV prevalence (Supplementary Figure S17) similar to the observations found in the 
no intervention scenario.
Discussion
This model illustrates how interventions, such as HAART and prophylactic HIV vaccines, can influ-
ence individual risk perception and behavior through multiple pathways. These interventions may result 
directly in HAART or vaccine optimism, since they may alter the utilities or perceived risks for an 
HIV− person interacting with someone who is offering unprotected sex. However, they also confer pro-
tective effects through other pathways. The first pathway is that optimism itself may increase the offers 
of unprotected sex, which can increase the perceived infection risk in the population and make some 
HIV− individuals more cautious than they would otherwise be. A second pathway occurs through dis-
ease dynamics: interventions reduce HIV transmission and prevalence, which increases the proportion 
of HIV− individuals in the population. This, in itself, protects HIV− individuals since any given sexual 
encounter is more likely to be with another HIV− individual, and hence the number of unprotected sex 
acts with HIV+ actors per HIV− individual decreases. At baseline parameter values, the decrease in 
per capita unprotected sex acts due to a changing composition of the population is a net decrease, i.e. 
the effects of changing population composition are outweighed by any increase due to optimism. We 
note that this is not a simple outcome of herd immunity, since individuals can choose protected sex or 
unprotected sex.
As a result of these other feedback loops, both HIV prevalence and the rate of unprotected sex acts 
with HIV+ actors, per HIV− individual decrease under both HAART and prophylactic vaccines, despite 
the effects of HAART and vaccine optimism. However, the decline is not as significant as it would have 
been if compensatory behavior did not emerge after the interventions. At other parameter values, HIV 
prevalence can increase as a result of the interventions. For example, we observed that when the effect of 
HAART optimism is sufficiently high, making the utility of unprotected sex sufficiently attractive, then 
HIV prevalence could actually rise under HAART (Supplementary Figure S4). Also, for both HAART 
and the vaccine, if individuals over-estimate the population coverage of the intervention, they will tend 
to interpret unprotected sex offers as evidence of HAART optimism or vaccine protection, rather than 
HIV+ status, which can have damaging consequences (Supplementary Figures S7, S13). Finally, if vac-
cine protection wanes after 10 years, then the burden of HIV incidence may simply be shifted to older 
age groups, which would necessitate booster programs.
This model makes several assumptions due to need for simplification or lack of data. Parameter val-
ues concerning prophylactic vaccines are based on preliminary assumptions since the effectiveness and 
duration of protection of such a vaccine were not known at the time of publication. In addition, the game 
theoretical model is a simplified representation of how individuals weigh their preferences; additional 
factors may influence the decision making process in real populations. The model does not include 
memory of past sexual encounters with specific individuals, or sexual network structure. Although the 
model includes age structure, there may be other heterogeneities that could influence results such as 
variable sexual activity levels, or social and cultural group identification. The model assumes that indi-
viduals who are offered unprotected sex increase their estimate of HIV prevalence in the population. This 
was motivated by studies that address risk factors and psychological determinants of behavior in HIV+ 
individuals40, showing that engaging in US is more frequent in HIV+ individuals. As such, since this is 
a relatively homogeneous and closed group with distinct norms and practices, we assume that individuals 
offered unprotected sex assume the other individual has a higher chance of being HIV+ . However, in 
other populations, the opposite might be true.
The relative ranking of utilities for different choices is based on studies showing preferences for 
unprotected sex amongst highly active individuals. Although relative rankings are easier to establish, 
it is difficult to quantify the precise values of these utilities, which is why we varied the value of UPS 
in the univariate sensitivity analysis. We found that increasing or decreasing this parameter influences 
prevalence and risk assessment as we might expect, but our primary qualitative conclusion that multiple 
pathways can determine behavior and prevalence remains unchanged under this sensitivity analysis. 
Furthermore, exploring the impact of homogeneously mixing core group dynamics on stable, concurrent 
partnerships with individuals outside the core group of interest (e.g. long-term partners) may also be rel-
evant41. Future work could improve the realism of the model with respect to decision making processes 
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and population structure (for instance, by allowing behavior and risk perception to be more heterogene-
ous in both HIV+ and HIV− groups); incorporate age-specific mortality rates; or attempt to replicate 
specific empirical findings concerning HAART. Future work could also better assess how prophylactic 
HIV vaccines could best be used, including optimal design of booster and catch-up programs.
We conclude that the behavioral pathways that are activated by introducing interventions are more 
complicated and numerous than the simple picture of potentially problematic or counter-productive 
behavioral responses usually suggests, and the pathways could be beneficial as well as harmful. Evaluations 
of the impact of HAART and potential prophylactic vaccines on risk perception and behavior should 
adopt a whole-population viewpoint regarding the effects of the intervention. This includes considering 
feedbacks that the interventions may introduce by altering dynamics of interaction between actors and 
their risk perception, population demographics (HIV prevalence), how these factors interact, and how 
they vary over time and across different age groups.
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